Illumina Inc Stock Price, News & Analysis

Illumina has formed a partnership with the Jean Perrin Center at Clermont-Ferrand University Hospital in France to evaluate comprehensive genomic profiling (CGP) in late-stage cancer patients. This collaboration will utilize data from the CELIA study to compare CGP effectiveness against standard care approaches, including small panel tests. The TruSight™ Oncology 500 assay will be employed to analyze genetic mutations in various cancer types, aiming to enhance precision oncology practices. The study seeks to solidify CGP's role in French healthcare and ultimately improve patient outcomes.

Illumina (NASDAQ: ILMN) has partnered with the National Cancer Center Japan for a research project focused on nasopharyngeal carcinoma, particularly prevalent in Asia. This study, part of the A-TRAIN initiative, aims to analyze blood-based genomic profiles of affected patients, contributing to personalized treatment development. Nasopharyngeal carcinoma has significant incidence rates in Southeast Asia, representing a critical area for new therapeutic strategies. The research involves up to 96 patients using Illumina's TruSight Oncology 500 ctDNA, highlighting regional collaboration for cancer treatment advancements.

Illumina, Inc. (NASDAQ: ILMN) will release its fourth quarter and full year 2021 financial results on February 10, 2022, after market close. The company's President and CEO, Francis deSouza, along with CFO Sam Samad, will host a conference call at 2:00 PM PT to discuss the results. Investors can access this call via Illumina's website or by dialing in. A replay will be available for 30 days post-event. Illumina focuses on enhancing health through genomic innovation and is a leader in DNA sequencing technologies.

Illumina (NASDAQ: ILMN) has announced a multi-year agreement with Nashville Biosciences, a subsidiary of Vanderbilt University Medical Center, to enhance drug development through large-scale genomics. This collaboration will utilize Illumina's next-generation sequencing technology to analyze data from VUMC's extensive biobank, which includes around 250,000 de-identified DNA samples. The initiative aims to identify disease targets, accelerate therapy development, and potentially lower costs, ultimately advancing personalized medicine efforts.

Illumina (NASDAQ: ILMN) has announced a multi-year partnership with Agendia to co-develop in vitro diagnostic tests for oncology, specifically targeting breast cancer. This collaboration aims to enhance the use of next-generation sequencing for decentralized testing. Agendia's MammaPrint test, which predicts breast cancer recurrence risk and is FDA-cleared, will be the first decentralized NGS-based test of its kind. The partnership seeks to leverage both companies' expertise to improve patient care and management globally.

Illumina has partnered with Boehringer Ingelheim to develop companion diagnostics for its oncology programs aimed at enhancing precision medicine for advanced cancer patients. The collaboration will fast-track therapy selection by adding companion diagnostic claims to Illumina's TruSight Oncology 500 assay. This initiative emphasizes the use of comprehensive genomic profiling to identify patients suited for novel therapies. Joydeep Goswami from Illumina expressed enthusiasm over the long-term partnership, highlighting its potential in unlocking new biomarkers critical for cancer treatment.

Illumina (NASDAQ: ILMN) reported a strong financial performance for 2021, with fourth-quarter revenue at approximately $1.190 billion (+25% YoY) and a full-year revenue of $4.517 billion (+39% YoY). The company anticipates 2022 revenue of $5.15-$5.24 billion, reflecting a growth of 14-16%. CEO Francis deSouza emphasized new partnerships in oncology and advancements in genomic technologies, including early cancer detection tests and innovative sequencing methods. These initiatives aim to enhance healthcare and drive further market penetration.

GRAIL has partnered with the OHSU Knight Cancer Institute to offer the advanced Galleri blood test, which aims to detect over 50 types of cancer early. The pilot program will be available to eligible patients, enhancing cancer detection methods significantly, as traditional screenings only cover a limited number of cancer types. Galleri's low false positive rate and high accuracy in identifying cancer origins are crucial in the fight against cancer, which claims over 600,000 lives annually in the U.S.

GRAIL announced a collaboration with Premier, Inc.'s PINC AI to enhance patient access to Galleri, a multi-cancer early detection blood test. This partnership aims to integrate AI-based alerts for clinicians to identify patients at elevated cancer risk. Community Health Network will pilot these alerts. The Galleri test can detect over 50 cancer types through a single blood draw, improving early detection and treatment outcomes. GRAIL emphasizes the importance of early cancer detection to increase survival rates, as many cancers are diagnosed late when treatment options are limited.